Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Michael A Horberg & Daniel B Klein. (2010) An update on the use of Atripla® in the treatment of HIV in the United States. HIV/AIDS - Research and Palliative Care 2, pages 135-140.
Read now
Read now
Birgitte R Hansen, Steen B Haugaard, Johan Iversen, Jens Ole Nielsen & Ove Andersen. (2004) Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review. Scandinavian Journal of Infectious Diseases 36:4, pages 244-253.
Read now
Read now
Hans Jürgen von Giesen, Hubertus Köller, Dominique de Nocker, Bernhard A. Haslinger & Gabriele Arendt. (2003) Long-Term Safety and Efficacy of NNRTI Within the Central Nervous System. HIV Clinical Trials 4:6, pages 382-390.
Read now
Read now
Articles from other publishers (10)
F Kaestner, K Anneken, C Mostert, D Reichelt, M Rothermundt, S Evers & I W Husstedt. (2012) Depression associated with antiretroviral drug therapy in HIV: case report and overview. International Journal of STD & AIDS 23:6, pages e14-e19.
Crossref
Crossref
R.Y. Carlier, P. de Truchis, S. Ronze, D. Mompoint, C. Vallée & J.C. Melchior. (2007) IRM du tissu adipeux abdominal et lipodystrophie VIH, étude cas-témoin. Journal de Radiologie 88:7-8, pages 947-956.
Crossref
Crossref
Greg Beaudoin, Bilge Diker, Jonathan B Angel & Karen F T Copeland. (2006) Effects of Highly Active Antiretroviral Therapy and Immune Recovery on CD8+ T-Cell-Mediated Inhibition of HIV-1 Transcription. JAIDS Journal of Acquired Immune Deficiency Syndromes 43:4, pages 393-400.
Crossref
Crossref
Cesar Fisac, Emilio Fumero, Manuel Crespo, Beatriz Roson, Elena Ferrer, Nuria Virgili, Esteban Ribera, Jose Maria Gatell & Daniel Podzamczer. (2005) Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 19:9, pages 917-925.
Crossref
Crossref
Hernando Knobel & Ana Guelar. (2004) Estrategias para optimizar la adherencia al tratamiento antirretroviral. Intervenciones en la pauta terapéutica. Enfermedades Infecciosas y Microbiología Clínica 22:2, pages 106-112.
Crossref
Crossref
Esteban Martínez, Juan A. Arnaiz, Daniel Podzamczer, David Dalmau, Esteban Ribera, Pere Domingo, Hernando Knobel, Melcior Riera, Enric Pedrol, Lluis Force, Josep M. Llibre, Ferran Segura, Cristóbal Richart, Cristina Cortés, Manuel Javaloyas, Miquel Aranda, Ana Cruceta, Elisa de Lazzari & José M. Gatell. (2003) Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection. New England Journal of Medicine 349:11, pages 1036-1046.
Crossref
Crossref
D Zucman. (2003) Évaluation rétrospective d'une cohorte de patients traités par l'association saquinavir/ritonavir 800/100 mg deux fois par jour. Médecine et Maladies Infectieuses 33:1, pages 15-19.
Crossref
Crossref
Henning Drechsler & William G. Powderly. (2002) Switching Effective Antiretroviral Therapy: A Review. Clinical Infectious Diseases 35:10, pages 1219-1230.
Crossref
Crossref
Marieke Wichers, Andre van der Ven & Michael Maes. (2002) Central nervous system symptoms related to the use of efavirenz in HIV-seropositive patients. Current Opinion in Psychiatry 15:6, pages 643-647.
Crossref
Crossref
Mike Youle. (2002) Strategies of HIV management — when to switch. AIDS 16, pages S151-S155.
Crossref
Crossref